SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
PARSHALL B LYNNE

(Last) (First) (Middle)
280 EAST GRAND AVENUE

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2017
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $14.25 05/18/2017 A 20,000 06/18/2017(1) 05/18/2027 Common Stock 20,000 $0.0 20,000 D
Explanation of Responses:
1. This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 18, 2018.
By: Peter S. Roddy For: B. Lynne Parshall 05/22/2017
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

       The undersigned, as a Section 16 reporting person of 
Cytokinetics, Incorporated (the Company), hereby constitutes and 
appoints Robert I. Blum and Peter S. Roddy, and each of them, the 
undersigned's true and lawful attorney-in-fact to

1.	complete and execute Forms 3, 4 and 5 and other forms and 
all amendments thereto as such attorney-in-fact shall in 
his or her discretion determine to be required or 
advisable pursuant to Section 16 of the Securities 
Exchange Act of 1934 (as amended) and the rules and 
regulations promulgated thereunder, or any successor laws 
and regulations, as a consequence of the undersigneds 
ownership, acquisition or disposition of securities of 
the Company; and

2.	do all acts necessary in order to file such forms with 
the Securities and Exchange Commission, any securities 
exchange or national association, the Company and such 
other person or agency as the attorney-in-fact shall deem 
appropriate.

       The undersigned hereby ratifies and confirms all that said 
attorneys-in-fact and agents shall do or cause to be done by virtue 
hereof.  The undersigned acknowledges that the foregoing attorneys-
in-fact, in serving in such capacity at the request of the 
undersigned, are not assuming,
 nor is the Company assuming, any of 
the undersigneds responsibilities to comply with Section 16 of the 
Securities Exchange Act of 1934 (as amended).

       This Power of Attorney shall remain in full force and effect 
until the undersigned is no longer required to file Forms 3, 4, and 
5 with respect to the undersigneds holdings of and transactions in 
securities issued by the Company, unless earlier revoked by the 
undersigned in a signed writing delivered to the Company and the 
foregoing attorneys-in-fact.
       
       IN WITNESS WHEREOF, the undersigned has caused this Power of 
Attorney to be executed as of this 18 day of May, 2017.


Signature:	/s/ B. Lynne Parshall

Print Name:	B. Lynne Parshall